lapatinib has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grabowski, T; Grześkowiak, E; Karbownik, A; Klupczynska, A; Kokot, ZJ; Moch, M; Plewa, S; Sobańska, K; Szałek, E; Wolc, A | 1 |
| Akhtar, S; Al-Khaldi, AT; Attur, S; Benter, IF; Chandrasekhar, B; Dhaunsi, GS; Sarkhou, F; Yousif, MH | 1 |
2 other study(ies) available for lapatinib and Alloxan Diabetes
| Article | Year |
|---|---|
A pharmacokinetic study on lapatinib in type 2 diabetic rats.
Topics: Animals; Antineoplastic Agents; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Lapatinib; Male; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Tandem Mass Spectrometry | 2018 |
The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Angiopathies; ErbB Receptors; Hyperglycemia; Lapatinib; Male; Molecular Targeted Therapy; Muscle, Smooth, Vascular; Phosphorylation; Primary Cell Culture; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction | 2015 |